SNTI - Senti Biosciences, Inc. Stock Price, Fair Value and News

$2.19+0.09 (+4.29%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SNTI Price Action

Last 7 days

3.8%

Last 30 days

9.5%

Last 90 days

58.7%

Trailing 12 Months

-69.3%

SNTI RSI Chart

SNTI Valuation

Market Cap

57.6M

Price/Earnings (Trailing)

-1.21

Price/Sales (Trailing)

7.22

Price/Free Cashflow

-1.15

SNTI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SNTI Fundamentals

SNTI Revenue

Revenue (TTM)

6.4M

SNTI Earnings

Earnings (TTM)

-47.6M

Earnings Growth (Yr)

37.21%

Earnings Growth (Qtr)

-23.03%

SNTI Profitability

Return on Equity

-585.9%

Return on Assets

-90.31%

Free Cashflow Yield

-87.33%

SNTI Investor Care

Shares Dilution (1Y)

472.95%

Diluted EPS (TTM)

-3.28

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.7M	5.4M	6.1M	6.4M
2023	4.5M	4.0M	3.2M	4.5M
2022	3.8M	4.4M	5.0M	4.3M
2021	1.1M	1.7M	2.2M	2.8M
2020	0	0	0	566.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

CEO	Dr. Timothy K. Lu M.D., Ph.D.
WEBSITE	sentibio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	122

Senti Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Senti Biosciences, Inc.? What does SNTI stand for in stocks?

SNTI is the stock ticker symbol of Senti Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Senti Biosciences, Inc. (SNTI)?

As of Wed Dec 03 2025, market cap of Senti Biosciences, Inc. is 57.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers.

Is Senti Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNTI is over valued or under valued. Whether Senti Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Senti Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNTI.

What is Senti Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SNTI's PE ratio (Price to Earnings) is -1.21 and Price to Sales (PS) ratio is 7.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNTI PE ratio will change depending on the future growth rate expectations of investors.